Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:MDNA CVE:NVH TSE:VSN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMDNAMedicenna TherapeuticsC$0.46+3.4%C$0.62C$0.42▼C$1.97C$37.96M2.900601114,544 shs53,914 shsNVHNovoheartC$0.53+1.9%C$0.53C$0.26▼C$0.72C$99.98MN/A33,593 shs23,066 shsVSNVeresenC$0.00C$11.40▼C$19.07C$5.81BN/A1.30 million shs1.15 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMDNAMedicenna Therapeutics+3.41%-15.74%-22.88%-49.44%-60.43%NVHNovoheart0.00%0.00%0.00%0.00%0.00%VSNVeresen0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMDNAMedicenna TherapeuticsC$0.46+3.4%C$0.62C$0.42▼C$1.97C$37.96M2.900601114,544 shs53,914 shsNVHNovoheartC$0.53+1.9%C$0.53C$0.26▼C$0.72C$99.98MN/A33,593 shs23,066 shsVSNVeresenC$0.00C$11.40▼C$19.07C$5.81BN/A1.30 million shs1.15 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMDNAMedicenna Therapeutics+3.41%-15.74%-22.88%-49.44%-60.43%NVHNovoheart0.00%0.00%0.00%0.00%0.00%VSNVeresen0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMDNAMedicenna Therapeutics 0.00N/AN/AN/ANVHNovoheart 0.00N/AN/AN/AVSNVeresen 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMDNAMedicenna TherapeuticsN/AN/AC$0.40 per share1.15C$0.07 per shareN/ANVHNovoheartC$423.50K236.08C$0.07 per share7.46C$0.12 per share4.34VSNVeresenN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMDNAMedicenna Therapeutics-C$25.98M-C$0.15N/AN/AN/A-533,640.00%-103.51%-32.80%N/ANVHNovoheartN/A-C$0.04N/AN/AN/AN/AN/AN/AN/AVSNVeresenN/AN/AN/AN/AN/AN/AN/AN/AN/ALatest NVH, VSN, and MDNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/30/2026Q1 2026MDNAMedicenna TherapeuticsN/A-C$0.06N/A-C$0.06N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthMDNAMedicenna TherapeuticsN/AN/AN/AN/AN/ANVHNovoheartN/AN/AN/AN/AN/AVSNVeresenC$1.005.27%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMDNAMedicenna Therapeutics3.302.684.65NVHNovoheart27.626.136.05VSNVeresenN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMDNAMedicenna Therapeutics0.43%NVHNovoheartN/AVSNVeresenN/AInsider OwnershipCompanyInsider OwnershipMDNAMedicenna Therapeutics22.57%NVHNovoheartN/AVSNVeresenN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMDNAMedicenna Therapeutics2083.42 millionN/ANot OptionableNVHNovoheartN/A188.64 millionN/ANot OptionableVSNVeresen147,000314.00 millionN/ANot OptionableNVH, VSN, and MDNA HeadlinesRecent News About These CompaniesVeresen Inc. Stock Price HistoryOctober 6, 2025 | investing.comJordan Cove parent company looks at financing, ownership options, expansionSeptember 28, 2023 | theworldlink.comTELD apologises after nearly 10,000 voters in Tanjong Pagar GRC receive two poll cards due to printer’s errorAugust 27, 2023 | channelnewsasia.comCJordan Cove donates more than $300,000 to defeat measureMay 22, 2023 | theworldlink.comTEncuentran al menos 60 cadáveres en provincia del Congo - ChronApril 26, 2023 | news.google.comNVeresen (TSE:VSN) Stock Price Passes Above Two Hundred Day ... - Defense WorldApril 18, 2023 | news.google.comNOregon DEQ opens comments on permit renewal for former Weyerhaeuser facilityApril 11, 2023 | theworldlink.comTBidders Can Structure Offers To Discourage The Use Of Rights Of ... - Mondaq News AlertsApril 5, 2023 | news.google.comNRecuperan 36 cadáveres en un pozo tras derrumbe en India - Hartford City News TimesMarch 31, 2023 | news.google.comNThe Right Of First Refusal And Good Faith In Your Business Contract ... - Mondaq News AlertsMarch 29, 2023 | news.google.comNBidders can Structure Offers to Discourage the Use of Rights of First ... - LexologyMarch 28, 2023 | news.google.comNPembina Pipeline : Gas Infrastructure - Marketscreener.comMarch 27, 2023 | news.google.comNBidders can Structure Offers to Discourage the Use of Rights of First ... - McMillan LLPMarch 27, 2023 | news.google.comNBBC Sounds - Assignment - Available EpisodesMarch 25, 2023 | bbc.co.ukThe Right of First Refusal and Good Faith in Your Business Contract ... - LexologyMarch 21, 2023 | news.google.comNLiquefied Natural Gas Market to See Massive Growth by 2029 ... - Digital JournalMarch 14, 2023 | news.google.comNNatural Gas Market Booming Worldwide( Forecast Period 2023-2029) With Top Player:BG Group plc, Apache Corporat - openPRMarch 14, 2023 | news.google.comNLong-term supply agreements and high inflation — what businesses ... - McCarthy Tétrault LLPMarch 9, 2023 | news.google.comNCEN: Reasonable CEF, But The Private Position Could Be A ... - Seeking AlphaMarch 8, 2023 | news.google.comNInsights and Takeaways From Our Top 10 Commercial Litigation ... - LexologyFebruary 28, 2023 | news.google.comNNVH, VSN, and MDNA Company DescriptionsMedicenna Therapeutics TSE:MDNAC$0.46 +0.02 (+3.41%) As of 05/22/2026 03:59 PM EasternMedicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.Novoheart CVE:NVHC$0.53 +0.01 (+1.92%) As of 11/20/2020Novoheart Holdings Inc. operates as a stem cell biotechnology company in the United States. The company offers an array of next-generation human heart tissue prototypes. It provides MyHeart platform products, including human pluripotent stem cell-derived cardiomyocytes, human ventricular cardiac anisotropic sheet assays, and human ventricular cardiac tissue strips assays. The company also offers screening and phenotyping services; and consultation services, including mapping and designing preclinical studies that involve human embryonic or induced pluripotent stem cell-derived cardiomyocytes, prototyping custom bioreactor designs, and developing custom software for streamlining of screening platforms and analysis of acquired data. Novoheart Holdings Inc. has a collaboration with AstraZeneca to develop human-specific in vitro functional model of heart failure with preserved ejection fraction. The company is based in Vancouver, Canada.Veresen TSE:VSNVeresen Inc is a Canada-based energy infrastructure company that owns and operates energy infrastructure assets across North America. The Company is engaged in three principal businesses: a pipeline transportation business consists of interests in the Alliance Pipeline, the Ruby Pipeline and the Alberta Ethane Gathering System (AEGS); a midstream business, which includes a partnership interest in Veresen Midstream Limited Partnership, which owns assets in western Canada, and an ownership interest in Aux Sable, which owns a natural gas liquids (NGL) extraction facility near Chicago, and other natural gas and NGL processing energy infrastructure, and a power business consists of a portfolio of assets in Canada. The Company's segments include Pipelines, Midstream, Power and Corporate. Alliance Pipeline owns and manages an integrated, high-pressure natural gas and NGL pipeline. Ruby Pipeline is a natural gas transmission system. AEGS is an integrated pipeline system. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
